4.6 Article

OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2-INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES

Journal

DEPRESSION AND ANXIETY
Volume 32, Issue 9, Pages 671-683

Publisher

WILEY
DOI: 10.1002/da.22403

Keywords

hypercapnia; panic; anxiety; orexin; hypocretin; hypothalamus; chemoreception; COPD; bronchitis; asthma

Funding

  1. Janssen Research and Development, LLC
  2. Indiana University Simon Cancer Center Basic Science Pilot [23-87597]
  3. NIA, NIH K [1K01AG044466]
  4. Indiana CTSI [UL1 RR025761]
  5. NIMH [R01 MH52619, R01 MH65702]

Ask authors/readers for more resources

BackgroundThe neuropeptides orexin A and B play a role in reward and feeding and are critical for arousal. However, it was not initially appreciated that most prepro-orexin synthesizing neurons are almost exclusively concentrated in the perifornical hypothalamus, which when stimulated elicits panic-associated behavior and cardiovascular responses in rodents and self-reported panic attacks and fear of dying in humans. More recent studies support a role for the orexin system in coordinating an integrative stress response. For instance, orexin neurons are highly reactive to anxiogenic stimuli, are hyperactive in anxiety pathology, and have strong projections to anxiety and panic-associated circuitry. Although the two cognate orexin receptors are colocalized in many brain regions, the orexin 2 receptor (OX2R) most robustly maps to the histaminergic wake-promoting region, while the orexin 1 receptor (OX1R) distribution is more exclusive and dense in anxiety and panic circuitry regions, such as the locus ceruleus. Overall, this suggests that OX1Rs play a critical role in mobilizing anxiety and panic responses. MethodsHere, we used a CO2-panic provocation model to screen a dual OX1/2R antagonist (DORA-12) to globally inhibit orexin activity, then a highly selective OX1R antagonist (SORA1, Compound 56) or OX2R antagonist (SORA2, JnJ10397049) to assess OX1R and OX2R involvement. ResultsAll compounds except the SORA2 attenuated CO2-induced anxiety-like behaviors, and all but the SORA2 and DORA attenuated CO2-induced cardiovascular responses. ConclusionsSORA1s may represent a novel method of treating anxiety disorders, with no apparent sedative effects that were present with a benzodiazepine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyra- zolo[3,4-d]azepines as 5-HT7/2 inhibitors leading to the identification of a clinical candidate

Curt A. Dvorak, Dale A. Rudolph, Diane Nepomuceno, Lisa Dvorak, Brian Lord, Ian Fraser, Pascal Bonaventure, Timothy Lovenberg, Nicholas I. Carruthers

Summary: A novel dual 5-HT7/5-HT2 receptor antagonist, 3-(4-Fluorophenyl)-2-isopropyl-2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene (4j), showed high affinity for both receptors with potential therapeutic efficacy in in vivo models for central 5-HT7 and 5-HT2A activity.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Article Immunology

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

Susana S. Correia, Guang Liu, Sarah Jacobson, Sylvie G. Bernier, Jenny V. Tobin, Chad D. Schwartzkopf, Emily Atwater, Elisabeth Lonie, Sam Rivers, Andrew Carvalho, Peter Germano, Kim Tang, Rajesh R. Iyengar, Mark G. Currie, John R. Hadcock, Christopher J. Winrow, Juli E. Jones

Summary: CYR119, a CNS-penetrant sGC stimulator, attenuates neuroinflammation by increasing cGMP production and shows neuroprotective effects in vivo models.

JOURNAL OF NEUROINFLAMMATION (2021)

Article Pharmacology & Pharmacy

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases

Susana S. Correia, Rajesh R. Iyengar, Peter Germano, Kim Tang, Sylvie G. Bernier, Chad D. Schwartzkopf, Jenny Tobin, Thomas W. -H. Lee, Guang Liu, Sarah Jacobson, Andrew Carvalho, Glen R. Rennie, Joon Jung, Paul A. Renhowe, Elisabeth Lonie, Christopher J. Winrow, John R. Hadcock, Juli E. Jones, Mark G. Currie

Summary: Effective treatments for neurodegenerative diseases are urgently needed as the global population ages. CY6463, a brain-penetrant sGC stimulator, has shown promise in preclinical models by improving neuronal activity, mediating neuroprotection, and enhancing cognitive performance.

FRONTIERS IN PHARMACOLOGY (2021)

Letter Genetics & Heredity

Phelan-McDermid syndrome: a classification system after 30 years of experience

Katy Phelan, Luigi Boccuto, Craig M. Powell, Tobias M. Boeckers, Conny van Ravenswaaij-Arts, R. Curtis Rogers, Carlo Sala, Chiara Verpelli, Audrey Thurm, William E. Bennett, Christopher J. Winrow, Sheldon R. Garrison, Roberto Toro, Thomas Bourgeron

Summary: Phelan-McDermid syndrome, initially known as 22q13 deletion syndrome, is now recognized to be associated with SHANK3 gene. To reduce confusion, a simple classification system has been proposed, dividing PMS into PMS-SHANK3 related and PMS-SHANK3 unrelated cases.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Article Pharmacology & Pharmacy

Identification and characterization of select oxysterols as ligands for GPR17

Anthony W. Harrington, Changlu Liu, Naomi Phillips, Diane Nepomuceno, Chester Kuei, Joseph Chang, Weixuan Chen, Steven W. Sutton, Daniel O'Malley, Ly Pham, Xiang Yao, Siquan Sun, Pascal Bonaventure

Summary: The study suggests that oxysterols, including 24S-HC, could be physiological activators for GPR17, regulating oligodendrocyte progenitor cell differentiation and myelination through receptor activation.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Meeting Abstract Medicine, Research & Experimental

CY6463, a CNS-penetrant sGC stimulator, elicits benefits in preclinical models of mitochondrial complex 1 deficiency

Emmanuel S. Buys, Susana S. Correia, Guang Liu, Joon Jung, John R. Hadcock, Peter Germano, Christopher J. Winrow, Juli E. Jones

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Meeting Abstract Medicine, Research & Experimental

Applying translational approaches for the nonclinical and clinical evaluation of the sGC stimulator CY6463 in CNS diseases

Christopher J. Winrow

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Meeting Abstract Neurosciences

Characterizing Disease-Associated Missense Mutations in the GABA Transporter, GAT1

Benjamin Throesch, Michelle Wennerholm, Pascal Bonaventure, Grace Woodruff

NEUROPSYCHOPHARMACOLOGY (2022)

Meeting Abstract Neurosciences

Darigabat Reduces Acute Psychological and Physiological Panic and Fear Symptoms Induced by CO2 Inhalation in Healthy Participants

Stacey Versavel, Rachel Gurrell, Ih Chang, Ann Dandurand, Sridhar Duvvuri, Amy Giugliano, Gina Pastino, Theresa Pham, Gabriel Jacobs, Koshar Safai Pour, Rob Zuiker, Raymond Sanchez, John Renger

NEUROPSYCHOPHARMACOLOGY (2022)

Article Medicine, General & Internal

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: atwo-part, randomised, double-blind, placebo-controlled, phase 1b trial

John H. Krystal, John M. Kane, Christoph U. Correll, David P. Walling, Matthew Leoni, Sridhar Duvvuri, Shrinal Patel, Ih Chang, Philip Iredale, Lillian Frohlich, Stacey Versavel, Pamela Perry, Raymond Sanchez, John Renger

Summary: The trial involved two parts with a total of 167 schizophrenia patients. The results showed that emraclidine once-daily treatment had good safety and tolerability, demonstrating potential for further investigation as a treatment for schizophrenia.

LANCET (2022)

Meeting Abstract Neurosciences

Characterizing Disease-Associated Missense Mutations in the GABA Transporter, GAT1

Benjamin Throesch, Michelle Wennerholm, Pascal Bonaven-Ture, Grace Woodruff

NEUROPSYCHOPHARMACOLOGY (2021)

Meeting Abstract Neurosciences

Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 Using [11C]MK-6884 Pet in Nonhuman Primates

Sridhar Duvvuri, Philip Iredale, Matthew Leoni, Vasily Belov, Nicolas Guehl, Sung-Hyun Moon, Maeva Dhaynaut, Peter Rice, Daniel Yokell, Georges El Fakhri, Marc Normandin, John Renger

NEUROPSYCHOPHARMACOLOGY (2021)

Meeting Abstract Neurosciences

CVL-231 as a Novel Positive Allosteric Modulator of Cholinergic M4 Receptors for the Treatment of Schizophrenia: Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia

John Krystal, John Kane, Christoph Correll, David Walling, Matthew Leoni, Sridhar Duvvuri, Ih Chang, Philip Iredale, Stacey Versavel, Lillian Frohlich, Shrinal PatelPamela Perry, Raymond Sanchez, John Renger

NEUROPSYCHOPHARMACOLOGY (2021)

Meeting Abstract Endocrinology & Metabolism

Neuroimaging of M4 muscarinic acetylcholine receptors using [11C]MK-6884 in rhesus macaques

Vasily Belov, Nicolas J. Guehl, Sridhar Duvvuri, Philip Iredale, Sung-Hyun Moon, Maeva Dhaynaut, Peter A. Rice, Daniel L. Yokell, John Renger, Georges El Fakhri, Marc D. Normandin

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2021)

Article Medicine, Research & Experimental

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists

Rahul Sasane, Amy Bartels, Michelle Field, Maria I. Sierra, Sridhar Duvvuri, David L. Gray, Sokhom S. Pin, John J. Renger, David J. Stone

Summary: The study found that tamsulosin users had a significantly higher incidence of Parkinson's disease compared to terazosin/alfuzosin/doxazosin users and matched controls. There was no significant difference in Parkinson's disease risk between terazosin/alfuzosin/doxazosin users and matched controls. These results suggest that tamsulosin may exacerbate Parkinson's disease progression.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available